Antibody-mediated neutralization of CXCL9 during established obesity conferred protection from hepatocellular damage (51), suggesting that activating the CXCL9 axis may represent an essential hallmark of MASLD progression. Here, CXCL9 is linked to obesity due to melanocortin 4 receptor deficiency.